25th Anniversary: Health Policy Turning Point Explained
- A major clinical trial, the SELECT trial, has revealed a potential increased risk of cardiovascular events - including heart attack, stroke, and cardiovascular death - in individuals with...
- the SELECT trial specifically focused on adults with obesity (BMI of 30 or higher) *and* pre-existing cardiovascular disease, such as heart attack, stroke, or peripheral artery disease.
- The absolute risk increase was relatively small - approximately 1.3 cardiovascular events per 100 person-years.
Ozempic and Cardiovascular Risk: new Findings Demand Closer Scrutiny
What Happened? A Closer Look at the SELECT Trial
A major clinical trial, the SELECT trial, has revealed a potential increased risk of cardiovascular events – including heart attack, stroke, and cardiovascular death – in individuals with obesity and established cardiovascular disease who were treated with semaglutide (Ozempic). The study,involving over 17,600 participants,showed a statistically significant,tho relatively small,increase in these events compared to a placebo group. This finding challenges previous assumptions about the cardiovascular safety of GLP-1 receptor agonists like semaglutide.
Understanding the SELECT Trial: Key Details
the SELECT trial specifically focused on adults with obesity (BMI of 30 or higher) *and* pre-existing cardiovascular disease, such as heart attack, stroke, or peripheral artery disease. Participants were randomly assigned to receive either 2.4 mg of semaglutide weekly or a placebo, along with their standard cardiovascular care. The primary outcome was the first occurrence of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, or unstable angina requiring hospitalization. Over an average of 3.4 years, the semaglutide group experienced a 9% increased risk of these events.
| Outcome | Semaglutide Group (n=8831) | Placebo Group (n=8801) | Hazard Ratio (95% CI) |
|---|---|---|---|
| Cardiovascular Death | 3.7% | 2.1% | 1.74 (1.11 to 2.73) |
| Nonfatal Myocardial Infarction | 2.6% | 1.9% | 1.33 (0.83 to 2.13) |
| Nonfatal Stroke | 3.7% | 3.0% | 1.22 (0.80 to 1.85) |
| Unstable Angina Requiring Hospitalization | 1.2% | 0.8% | 1.48 (0.76 to 2.88) |
What Does This Mean? Separating Risk and Benefit
It’s crucial to avoid oversimplification. The absolute risk increase was relatively small – approximately 1.3 cardiovascular events per 100 person-years. However, for individuals already vulnerable due to existing heart disease, even a small increase is significant. Semaglutide remains highly effective for weight loss and improving metabolic health, but this trial highlights the need for careful patient selection and monitoring. The benefits of weight loss itself can *reduce* cardiovascular risk,creating a complex interplay.